Category Archives: Data Exclusivity

RCEP negotiators must fix the damaging provisions that remain a threat to public health

Hyderabad, July 21, 2017 – As negotiators for the Regional Comprehensive Economic Partnership (RCEP) trade agreement meet for another round of negotiations in Hyderabad next week, networks of people living with HIV/AIDS  from different parts of the country, public health experts from the … Continue reading

Posted in Data Exclusivity, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, Uncategorized | Leave a comment

Company sues Ukraine in bid to corner hepatitis C drug market

By Josh Kovensky, KyivPost | June 16, 2017 A doctor checks a patient for Hepatitis C in Zaporizhiya. As much as 10 percent of the Ukrainian population could be infected with the disease. Photo by UNIAN Multinational pharmaceutical firm Gilead Sciences has … Continue reading

Posted in Data Exclusivity, ISDS, Uncategorized | Leave a comment

The Trump Executive Order on drug prices: not what was promised nor needed, and contrary to US self interest

Source: Medium Emily Kopp has a big scoop for Kaiser Health News. She has obtained a six page document outlining the draft provisions or objectives of a proposed Presidential Executive Order (EO) on drug prices. She has shared some of … Continue reading

Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR Enforcement, Special 301 report, Uncategorized, UNHLP report, US Pressure | Leave a comment

June 2017 Alert: Pressure on countries hiked by US on IP

The US government is stepping up on TRIPS plus pressure through bilateral forums based on a US law that passed under Obama to strengthen IPR enforcement and the 301 process. Countries targeted include India, Indonesia, China, Thailand, Ukraine in Asia … Continue reading

Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR Enforcement, Special 301 report, Uncategorized, UNHLP report, US Pressure | Leave a comment

MSF response on RCEP negotiations in the Philippines

Source: MSF Access Campaign New Delhi, 8 May 2017 – The Philippines is set to host the 18th round of the Regional Comprehensive Economic Partnership (RCEP) trade agreement’s negotiations in Manila this week. Negotiators from the ten members of the … Continue reading

Posted in Data Exclusivity, Evergreening, Investor state dispute, IPR Enforcement, ISDS, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized, WTO | Leave a comment

The expanding universe of IP

Source: The Hindu Granting data exclusivity for clinical trials would undermine access to medicines April 26 is World Intellectual Property (IP) day. Over the years, global IP standards have steadily expanded beyond World Trade Organisation (WTO) requirements, thanks to free … Continue reading

Posted in Data Exclusivity, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

Switzerland wants stricter intellectual property rules in India that could harm generic drug makers

By Jyotsna Singh, Scroll | March 23, 2017 Developed countries continue to put pressure on India to move to stricter intellectual property regimes that would favour multinational pharmaceutical countries over generic drug manufacturers. A new leaked document shows that the … Continue reading

Posted in Data Exclusivity, EFTA-India FTA, Evergreening, Patent, Uncategorized | Leave a comment